Inactive Instrument

TURG POIN

Equities

TPTX

US90041T1088

Turning Point Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022

May 10, 2022 at 04:05 pm

Turning Point Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was USD 0.429 million compared to USD 25.21 million a year ago. Net loss was USD 74.45 million compared to USD 35.5 million a year ago. Basic loss per share from continuing operations was USD 1.5 compared to USD 0.73 a year ago.

Latest news about TURG POIN

Turning Point Therapeutics, Inc.(NasdaqGS:TPTX) dropped from S&P Global BMI Index	22-08-19	CI
Turning Point Therapeutics, Inc.(NasdaqGS:TPTX) dropped from S&P Biotechnology Select Industry Index	22-08-19	CI
Turning Point Therapeutics, Inc.(NasdaqGS:TPTX) dropped from S&P TMI Index	22-08-19	CI
Bristol-Myers Squibb Completes Acquisition of Turning Point Therapeutics	22-08-17	MT
Turning Point Therapeutics, Inc. Announces Executive Changes	22-08-17	CI
Turning Point Therapeutics, Inc.(NasdaqGS:TPTX) dropped from NASDAQ Composite Index	22-08-17	CI
Bristol Myers, Turning Point Say Regulatory Waiting Period for Acquisition Expires; Deal to Close Wednesday	22-08-16	MT
Bristol-Myers Squibb Company completed the acquisition of Turning Point Therapeutics, Inc. from a group of shareholders..	22-08-14	CI
Biotech stocks pin bounce back hopes on M&A boost	22-08-12	RE
Turning Point Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-08	CI
Turning Point Therapeutics, Inc. Provides Operational and Clinical Update	22-08-08	CI
Bristol Myers Squibb Extends Turning Point Tender Offer	22-07-19	MT
Turning Point Therapeutics, Inc.(NasdaqGS:TPTX) dropped from NASDAQ Biotechnology Index	22-07-18	CI
Turning Point Therapeutics to Work With University of Texas MD Anderson Cancer Center on Precision Cancer Therapies	22-06-24	MT
Turning Point Therapeutics, Inc. and The University of Texas MD Anderson Cancer Center to Advance Precision Cancer Therapies	22-06-24	CI
Guggenheim Downgrades Turning Point Therapeutics to Neutral From Buy, Adjusts Price Target to $76 From $72	22-06-13	MT
SVB Securities Downgrades Turning Point Therapeutics to Market Perform From Outperform, Adjusts Price Target to $76 From $101	22-06-13	MT
Oppenheimer Downgrades Turning Point Therapeutics to Market Perform From Outperform	22-06-06	MT
Cowen Downgrades Turning Point Therapeutics to Market Perform from Outperform	22-06-06	MT
HC Wainwright Cuts Turning Point Therapeutics to Neutral From Buy, Price Target to $76 From $161	22-06-06	MT
Wells Fargo Downgrades Turning Point Therapeutics to Equalweight From Overweight, Adjusts Price Target to $76 From $85	22-06-06	MT
US Stocks Decline on Friday After Jobs Report	22-06-03	MT
US Stocks Finish Holiday-Shortened Week Lower as May Unemployment Rate Holds Steady	22-06-03	MT
Sector Update: Health Care Stocks Dragged Lower in Sinking Friday Markets	22-06-03	MT
Equities Fall Midday After May Unemployment Rate Remains Unchanged	22-06-03	MT

Chart TURG POIN

Duration

Period

More charts

Company Profile

Turning Point Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in designing and developing therapies that target genetic drivers of cancer to improve the lives of patients. It develops a macrocycle platform from which it designs its pipeline of small, compact tyrosine kinase inhibitors (TKIs). The TKIs generated from its drug discovery platform address unmet needs in TKI naive and resistance settings. The Company's drug candidate, repotrectinib (TPX-0005), is in Phase I/II trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with NTRK+ or ALK+ advanced solid tumors. Its multi-cohort Phase II registrational portion of TRIDENT-1 is ongoing at sites in North America, Europe and the Asia-Pacific regions. The Company's pipeline includes multi-targeted kinase inhibitors: TPX-0046 (a novel RET inhibitor), Elzovantinib (TPX-0022) (a novel MET/CSF1R/SRC inhibitor) and TPX-0131.

Sector

More about the company